Three monoclonal antibodies against the serpin protease nexin-1 prevent protease translocation

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 29-40

  Kousted, Tina M ^a   Skjoedt, Karsten ^b   Petersen, Steen V ^a   Koch, Claus ^b   Vitved, Lars ^b   Sochalska, Maja ^a   Lacroix, Céline ^a   Andersen, Lisbeth M ^a   Wind, Troels ^a   Andreasen, Peter A ^a   Jensen, Jan K ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cancer; Glia derived nexin; Inhibitory antibody; Serine protease; SERPIN E2

Indexed keywords

HEPARIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33; MONOCLONAL ANTIBODY 34; MONOCLONAL ANTIBODY 39; PROTEASE NEXIN I; PROTEINASE; THROMBIN; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BETA SHEET; CIRCULAR DICHROISM; CONTROLLED STUDY; EPITOPE MAPPING; ESCHERICHIA COLI; FEMALE; GENE MUTATION; GLYCOSYLATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

CANCER; GLIA-DERIVED NEXIN; INHIBITORY ANTIBODY; SERINE PROTEASE; SERPIN E2;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPITOPE MAPPING; ESCHERICHIA COLI; GLYCOSYLATION; HEPARIN; HUMANS; KINETICS; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN CONFORMATION; PROTEIN TRANSPORT; SERPIN E2; SURFACE PLASMON RESONANCE; TIME FACTORS;

EID: 84891879068     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0340     Document Type: Article

References (50)

1. Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
2. Ye S, Goldsmith EJ. Serpins and other covalent protease inhibitors. Curr Opin Struct Biol 2001; 11: 740-745.
3. Wind T, Hansen M, Jensen JK, et al. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biological Chem 2002; 383: 21-36.
4. Huntington JA. Shape-shifting serpins--advantages of a mobile mechanism. Trends Biochem Sci 2006; 31: 427-435.
5. Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011;9 (Suppl 1): 26-34.
6. Wallace A, Rovelli G, Hofsteenge J, et al. Effect of heparin on the glia-derivednexin-thrombin interaction. Biochem J 1989; 257: 191-196.
7. Rovelli G, Stone SR, Guidolin A, et al. Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1. Biochemistry 1992; 31: 3542-3549.
8. Herndon ME, Stipp CS, Lander AD. Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology 1999; 9: 143-155.
9. Richard B, Bouton MC, Loyau S, et al. Modulation of protease nexin-1 activity by polysaccharides. Thromb Haemost 2006; 95: 229-235.
10. Scott RW, Bergman BL, Bajpai A, et al. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1985; 260: 7029-7034.
11. Evans DL, McGrogan M, Scott RW, et al. Protease specificity and heparin binding and activation of recombinant protease nexin I. J Biol Chem 1991; 266: 22307-22312.
12. Stone SR, Brown-Luedi ML, Rovelli G, et al. Localization of the heparin-binding site of glia-derived nexin/protease nexin-1 by site-directed mutagenesis. Biochemistry 1994; 33: 7731-7735.
13. Li W, Huntington JA. Crystal structures of protease nexin-1 in complex with heparin and thrombin suggest a 2-step recognition mechanism. Blood 2012; 120: 459-467.
14. Jensen JK, Dolmer K, Gettins PG. Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1. J Biol Chem 2009; 284: 17989-17997.
15. Kousted TM, Jensen JK, Gao S, et al. Protease Nexin 1-a serpin with a possible pro-invasive role in cancer. In: Behrendt N, editor. Matrix Proteases in Health and Disease Wiley-VCH Verlag GmbH & Co; 2012. pp. 251-281.
16. Dupont DM, Madsen JB, Kristensen T, et al. Biochemical properties of plasminogen activator inhibitor-1. Frontiers Biosci 2009; 14: 1337-1361.
17. Bouton MC, Boulaftali Y, Richard B, et al. Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 2012; 119: 2452-2457.
18. Boulaftali Y, Francois D, Venisse L, et al. Endothelial Protease Nexin-1 Is a Novel Regulator of A Disintegrin and Metalloproteinase 17 Maturation and Endothelial Protein C Receptor Shedding via Furin Inhibition. Arterioscler Thromb Vasc Biol 2013; 33: 1647-1654.
19. Selbonne S, Azibani F, Iatmanen S, et al. In vitro and in vivo antiangiogenic properties of the serpin protease nexin-1. Mol Cell Biol 2012; 32: 1496-1505.
20. McKee CM, Xu D, Cao Y, et al. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest 2012; 122: 4025-4036.
21. Bijnens AP, Gils A, Stassen JM, et al. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity. J Biol Chem 2001; 276: 44912-44918.
22. Bijnens AP, Ngo TH, Gils A, et al. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1. Thromb Haemost 2001; 85: 866-874.
23. Verhamme I, Kvassman JO, Day D, et al. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 1999; 274: 17511-17517.
24. Naessens D, Gils A, Compernolle G, et al. Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition. Thromb Haemost 2003; 90: 52-58.
25. Dupont DM, Blouse GE, Hansen M, et al. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 2006; 281: 36071-36081.
26. Gorlatova NV, Elokdah H, Fan K, et al. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function. J Biol Chem 2003; 278: 16329-16335.
27. Schousboe SL, Egelund R, Kirkegaard T, et al. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F. Thromb Haemost 2000; 83: 742-751.
28. Wind T, Jensen MA, Andreasen PA. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding. Eur J Biochem 2001; 268: 1095-1106.
29. Bijnens AP, Gils A, Knockaert I, et al. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 2000; 275: 6375-6380.
30. Naessens D, Gils A, Compernolle G, et al. Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1. J Thromb Haemost 2003; 1: 1028-1033.
31. Debrock S, Declerck PJ. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop. Thromb Haemost 1998; 79: 597-601.
32. Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 2002; 277: 43858-43865.
33. Gao S, Krogdahl A, Sorensen JA, et al. Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol 2008; 44: 309-313.
34. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002; 30: E9.
35. Bager R, Kristensen TK, Jensen JK, et al. Urokinase-type plasminogen activatorlike proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. J Biol Chem 2012; 287: 27526-27536.
36. Tom R, Bisson L, Durocher Y. Transfection of HEK293-EBNA1 Cells in Suspension with Linear PEI for Production of Recombinant Proteins. CSH Protocols 2008; 2008: pdb prot4977.
37. Jensen JK, Wind T, Andreasen PA. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand. FEBS Lett 2002; 521: 91-94.
38. Jensen JK, Thompson LC, Bucci JC, et al. Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 2011; 286: 29709-29717.
39. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
40. Reading CL. Theory and methods for immunization in culture and monoclonal antibody production. J Immunol Methods 1982; 53: 261-291.
41. Nielsen LS, Andreasen PA, Grondahl-Hansen J, et al. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Thromb Haemost 1986; 55: 206-212.
42. Munch M, Heegaard C, Jensen PH, et al. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies. FEBS Lett 1991; 295: 102-106.
43. Futamura A, Gettins PG. Serine 380 (P14)--> glutamate mutation activates antithrombin as an inhibitor of factor Xa. J Biol Chem 2000; 275: 4092-4098.
44. Lawrence DA, Olson ST, Palaniappan S, et al. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 1994; 33: 3643-3648.
45. Berkenpas MB, Lawrence DA, Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 1995; 14: 2969-2977.
46. De Taeye B, Gils A, Declerck PJ. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant? Thromb Haemost 2004; 92: 898-924.
47. Carrell RW, Stein PE. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe-Seyler 1996; 377: 1-17.
48. Jensen JK, Gettins PG. High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci 2008; 17: 1844-1849.
49. Dementiev A, Dobo J, Gettins PG. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J Biol Chem 2006; 281: 3452-3457.
50. Rubinstein ND, Mayrose I, Halperin D, et al. Computational characterization of B-cell epitopes. Mol Immunol 2008; 45: 3477-3489.